References
- Iudicello A, Alberghini L, Benini G, et al. Expanded access programme: looking for a common definition. Trials. 2016;17(1):21.
- Jarow JP, Lurie P, Ikenberry SC, et al. Overview of FDA's expanded access program for investigational drugs. Ther Innov Regul Sci. 2017;51(2):177–179.
- Setia S, Ryan NJ, Nair PS, et al. Evolving role of pharmaceutical physicians in medical evidence and education. Adv Med Educ Pract. 2018;9:777–790.
- Lewis JR, Lipworth W, Kerridge I, et al. Dilemmas in the compassionate supply of investigational cancer drugs. Intern Med J. 2014;44(9):841–845.
- Puthumana J, Miller JE, Kim J, et al. Availability of investigational medicines through the US Food and Drug Administration's expanded access and compassionate use programs. JAMA Netw Open. 2018;1(2):e180283.
- Patil S. Early access programs: benefits, challenges, and key considerations for successful implementation. Perspect Clin Res. 2016; 7(1):4–8.
- Feit NZ, Goldman DA, Smith E, et al. Use, safety, and efficacy of single-patient use of the US Food and Drug Administration Expanded Access Program. JAMA Oncol. 2019;5(4):570–572.
- Fountzilas E, Said R, Tsimberidou AM. Expanded access to investigational drugs: balancing patient safety with potential therapeutic benefits. Expert Opin Investig Drugs. 2018;27(2):155–162.
- Mackey TK, Schoenfeld VJ. Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;14(1):17.
- Miller JE, Ross JS, Moch KI, et al. Characterizing expanded access and compassionate use programs for experimental drugs. BMC Res Notes. 2017;10(1):350.
- Caplan AL, Teagarden JR, Kearns L, et al. Fair, just and compassionate: a pilot for making allocation decisions for patients requesting experimental drugs outside of clinical trials. J Med Ethics. 2018;44(11):761–767.
- Mackey TK, Schoenfeld VJ. Going “social” to access experimental and potentially life-saving treatment: an assessment of the policy and online patient advocacy environment for expanded access. BMC Med. 2016;14(1):17.
- Medscape. How to improve access to compassionate-use drugs [Internet]. Medscape; 2015 [cited 2020 Oct 19]. Available from: https://www.medscape.com/viewarticle/854706.
- Raus K. An analysis of common ethical justifications for compassionate use programs for experimental drugs. BMC Med Ethics. 2016;17(1):60.
- Enterline L, Antoun M, Joines J. Access options for investigational products [Internet]; 2017 [cited 2020 Oct 19]. Available from: https://www.evidera.com/wp-content/uploads/2017/11/Access-Options-for-Investigational-Products.pdf.
- Bunnik E, Aarts N, van de Vathorst S. Views and experiences of physicians in expanded access to investigational views and experiences of physicians in expanded access to investigational drugs. Clin Ther. 2017;39(8):e96.
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–2194.
- Indian Council of Medical Research. National ethical guidelines for biomedical and health research involving human participants [Internet]; 2017 [cited 2020 Oct 19]. Available from: https://main.icmr.nic.in/sites/default/files/guidelines/ICMR_Ethical_Guidelines_2017.pdf.
- Guidelines for ethical review of clinical research or research involving human subjects [Internet]. Medical Review and Ethics Committee, Ministry of Health Malaysia; 2006. [cited 2020 Oct 19]. Available from: http://www.nccr.gov.my/index.cfm?menuid=26&parentid=17.
- Human Biomedical Research Act [Internet]. Singapore Statutes Online; 2015 [cited 2020 Oct 19]. Available from: https://sso.agc.gov.sg/Act/HBRA2015.
- Regulations for good clinical practice [Internet]. Ministry of Health and Welfare, Republic of China; 2014. [cited 2020 Oct 19]. Available from: https://law.moj.gov.tw/ENG/LawClass/LawAll.aspx?pcode=L0030056.
- A researcher handbook for SIRB approval [Internet]. Siriraj Institutional Review Board; 2014. Available from: https://www.si.mahidol.ac.th/sirb/Eng/index.html.
- Moerdler S, Zhang L, Gerasimov E, et al. Physician perspectives on compassionate use in pediatric oncology. Pediatr Blood Cancer. 2019;66(3):e27545.
- Gerasimov E, Donoghue M, Bilenker J, et al. Before it's too late: multistakeholder perspectives on compassionate access to investigational drugs for pediatric patients with cancer. Am Soc Clin Oncol Educ Book. 2020;40:1–e227.
- Caplan AL, Ray A. The ethical challenges of compassionate use. JAMA. 2016;315(10):979–980.
- Compassionate use navigator [Internet]. Washington: KidsvCancer; 2020 [cited 2020 Oct 19]. Available from: https://www.kidsvcancer.org/compassionate-use/.
- The EA navigator mission [Internet]. Washington: Reagan-Udall Foundation [cited 2020 Oct 19]. Available from: https://navigator.reaganudall.org/expanded-access-navigator.